Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2011-08-16
2011-08-16
Leavitt, Maria (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S455000, C435S456000
Reexamination Certificate
active
07998734
ABSTRACT:
The invention includes a composition comprising a recombinant adeno-associated viral vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5′ and 3′ untranslated regions and a transcription termination.
REFERENCES:
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5547932 (1996-08-01), Curiel et al.
patent: 5817784 (1998-10-01), Theill et al.
patent: 5834266 (1998-11-01), Crabtree et al.
patent: 5834306 (1998-11-01), Webster et al.
patent: 5846528 (1998-12-01), Podsakoff et al.
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: 5866552 (1999-02-01), Wilson et al.
patent: 6342390 (2002-01-01), Wiener et al.
patent: 88 116 366 (1983-09-01), None
patent: WO 96/15777 (1966-05-01), None
patent: WO 96/18727 (1996-06-01), None
patent: WO 98/09657 (1998-03-01), None
Kung, et al. In Vivo Expression of Therapeutic levels of Human F.I.X. using a recombinant Adeno-Associated Viral (AAV) Vector,Blood, 1996, 88, 273.
Kessler, et al., “Gene Delivery to Skeletal Muscle Results in Sustained Expression and Systemic Delivery of a Therapeutic Protein”,Proc. Natl. Acad. Sci. USA, 1996, 93, 14082-14087.
Anson, et al.,Embo J., 1984, 3, 1053-1060.
Carter,Curr. Opin. Biotech, 1992, 3, 533-539.
Cheung, et al.,Proc. Natl. Acad. Sci. USA, 1996, 93, 11068-11073.
Dai, et al.,Proc. Natl. Acad. Sci. USA, 1995, 92, 1401-1405.
Evans, et al.,Proc. Natl. Acad. Sci. USA, 1989, 86, 10095-10099.
Evans, et al.,Blood, 1989, 74, 207-212.
Fisher, et al.,J. Virol, 1996, 70, 520-532.
Fujikawa, et al., “Factor XI”,Molecular Basis of Thrombosis and Hemostasis, High and Roberts, eds, Marcel Dekker, Inc., 1995.
Hathaway and Goodnight, “Laboratory Measurement of Hemostasis and Thrombosis”,Disorders of Hemostasis and Thrombosis: A Clinical Guide, 1993, 21-29.
High, “Factor IX” Molecular Structure, Epitopes and Mutations Associated with Inhibitor Formation, Louis M. Aledort, eds., 1995, 79-85.
High, et al., “Factor IX” Molecular Basis of Thrombosis and Hemostasis, Marcel Dekker, Inc, eds., 1995, 215-237.
Jallat, et al.,EMBO J, 1990, 9, 3295-3301.
Jaye, et al.,Nucl. Acids Res., 1983, 11, 2325-2335.
Kaplitt, et al.,Nature Genet., 1994, 8, 148-154.
Katayama, et al.,Proc. Natl. Acad. Sci. USA, 1979, 76, 4990-4994.
Kay, et al.,Science, 1993, 262, 117-119.
Kay et al.,Proc. Natl. Acas. Sci. USA, 1994, 91, 2353-2357.
Kay, et al.,T.I.G., 1994, 10, 253-257.
Kotin,Human Gene Therapy, 1994, 5, 793-801.
Kurachi, et al.,Proc. Natl. Acad. Sci. USA, 1982, 79, 6461-6464.
Kurachi, et al.,J Biol. Chem., 1995, 270, 5276-5281.
Lai, et al., “Factor XIII”,Molecular Basis of Thrombosis and Hemostasis, High and Roberts, eds., Marcel Dekker, Inc. 1995.
McLaughin, et al.,J. Virol., 1988, 62, 1963-1973.
Parker Ponder, “Gene Therapy for Blood Protein Deficiencies”,Gene Transfer in Cardiovascular Biology: Experimental Approaches and Therapeutic Implications, 1996, Keith March, eds.
Pendurthi, et al.,Thromb Res., 1992, 65, 177-186.
Petersen, et al., “Factor VII”,Molecular Basis of Thrombosis and Hemostasis, High and Roberts, eds., Marcel Dekker, Inc. 1995.
Ross, et al.,Human Gene Therapy, 1996, 7, 1781-1790.
Samulski, et al.,J. Virol., 1989, 63, 3822-3828.
Sarkar, et al.,Genomics, 1990, 6, 133-143.
Skulimowski, et al.,Method Mol. Genet., 1995, 7, 3-12.
Suzuki., “Protein C”,Molecular Basis of Thrombosis and Hemostasis, High and Roberts, eds., Marcel Dekker, Inc. 1995.
Tripathy, et al.,Nature Med., 1996, 2, 545-550.
Tripathy, et al.,Proc. Natl. Acad. Sci. USA, 1996, 93, 10876-10880.
Tuddenham, “Factor VIII”,Molecular Basis of Thrombosis and Hemostasis, High and Roberts, eds., Marcel Dekker, Inc, 1995.
Walter, et al.,Proc. Natl. Acad. SciUSA, 1996, 93, 3056-3061.
Watzke, et al., “Factor X”,Molecular Basis of Thrombosis and Hemostasis, High and Roberts, eds., Marcel Dekker, Inc, 1995.
Wu, et al.,Gene, 1990, 86, 275-278.
Yang, et al.,Hum, Mol. Genet., 1996, 5, 1703-1712.
Yoshitake, et al.,Biochemistry, 1985, 24, 3736-3750.
Gnatenko, et al., “Generation and Characterization of Recombinant Adeno-Associated Viral (rAAV) Vectors for Factor VIII gene Therapy”,Blood, 1996, 88(10), Part ½, 139A, Abstract 543, XP001053457.
Kessler, et al., “Gene Delivery to Skeletal Muscle Results in Sustained Expression and Systemic Delivery of a Therapeutic Protein”,Proc. Natl. Acad. SciUSA., 1996, 93(24), 14082-14087, XP002287407.
Koerberl, et al., “Persistent Expression of Human Clotting Factor IX from Mouse Liver after Intravenous Injection of Adeno-Associated Virus Vectors”,Proc. Natl. Acad. Sci. USA, 1997, 94(4), 1426-1431, XP002287408.
Chen, et al., “Comparison of Retroviral and Adeno-Associated Viral Vectors Designed to Express Human Clotting Factor IX”,Human Gene Therapy, 1997, 8(2), 125-135, XP009029448.
Wiener, et al., “Stable Production in Vitro of Human Coagulation Factor IX Expressed from Adeno-Associated Virus”,Blood, 1996, 88(10), part ½, 138A, Abstract 541, XP008032518.
Kotin, “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy”, 1994, 5, 793-801, XP002911111.
Fisher, et al., “Recombinant Adeno-Associated Virus for Muscle Directed Gene Therapy”, Database Biosis [Online] Biosciences Information Service, 1997, Abstract, XP 002287409.
Richards, F.M., “Protein Stability: Still an Unsolved Problem”,Cell Mol. Life Sci., 1997, 53(10), 790-802.
Lai, et al., “Recombinant Adeno-Associated Virus Type-2-Mediated Gene Delivery in to the RPE65-/- Knockout mouse Eye Results in Lamented Rescue”,Genetic vaccines and Therapy, 2004, 2,3, 1-15.
Miao, et al., “Nonrandom Transduction of Recombinant Adeno-Associated Virus Vectors in Mouse Hepatocytes in Vivo: Cell Cycling does not Influence Hepatocyte Transduction”,J. of Virology, Apr. 2000, 3793, 38-3.
Wang, et al., “Construction of Human Factor IX Expression Vectors in Retroviral Frames Optimized for Muscle Cells”,Human Gene Ther., 1996, 7(14), 1743-1756.
Anderson., 1998,Nature, 392, 25.
Muzyczka.,J. Clin. Invest., 1994, 94, 1351.
Smith, et al.,Nat. Genet., 1993, 5(4), 397-402.
Miyanohara, et al.,New Biol., 1992, 4(3), 238-246.
Roman, et al.,Somatic Cell and Molecular Genetics., 1992, 18, 247-258.
Kaufman, et al.,Methods in Enzymology, 185, 487-511, 1997.
Herzog Roland W.
High Katherine A.
Leavitt Maria
The Children's Hospital of Philadelphia
Woodcock & Washburn LLP
LandOfFree
Methods and compositions for use in gene therapy for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for use in gene therapy for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for use in gene therapy for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2693007